Exosome for Early Diagnosis of Bipolar Affective Disorder
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05915312 |
|
Recruitment Status :
Not yet recruiting
First Posted : June 23, 2023
Last Update Posted : June 23, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Objectives: Bipolar disorder (BD) is a chronic and recurrent mental illness characterized by depressive episodes and manic or hypomanic episodes, leading to severe functional impairment and cognitive damage. Unfortunately, it is difficult to accurately distinguish between major depressive disorder (MDD) and BD in the early stages, resulting in misdiagnosis and mistreatment. According to statistics, only 20% of BD patients with initial depressive symptoms receive a correct diagnosis within the first year of onset, with an average delay of 5-10 years from onset to final diagnosis. BD patients are often treated with antidepressant medication systematically due to being diagnosed with MDD, affecting the disease course and clinical outcomes. The current study aims to explore the role of peripheral exosomes as biomarker to distinguish BD from MDD in early stage.
Methods: The study includes two stages: the first stage is a case-control study, comparing the concentrations of peripheral blood exosome metabolites (microRNA and related proteins) among three groups (BD patients, MDD patients, and healthy controls, n=30 per group) to identify target microRNA and proteins with statistically significant differences. The "latent class analysis (LCA)" on target microRNA and protein will be performed on all samples to observe whether it can effectively distinguish bipolar disorder, depressive episode, and healthy participants. Then, based on the LCA analysis results, "receiver operating characteristic (ROC)" analysis will be conducted to further determine the optimal concentration cut-off value for each indicator and ultimately determine the target biomarkers. The second stage is a clinical validation study in which subjects, who come from an on-going trial and initiated with a depressive episode and were followed up for five years at least, are divided into two groups (MDD group and BD group, n=20 respectively) based on whether they have hypomanic/manic episodes currently or previously, according to the DSM-5 diagnosed with SCID-5. All target biomarkers will be test in peripheral blood samples reserved at the initial stage to detect whether the diagnosis indicated by the biomarkers is consistent with diagnosis by DSM-5. As well as the accuracy of predicting diagnosis, the correlation between specific biomarkers and treatment response, clinical outcome, and adverse reactions will also be observed.
Discussion: It is difficult to explore central nervous system diseases through the peripheral system in the context of the blood-brain barrier. However, exosomes can freely pass through the blood-brain barrier and serve as a good medium for connecting the peripheral system and the central nervous system. This study aims to explore plasma exosome microRNAs and related proteins as biological markers for early diagnosis of bipolar disorder, for example, which microRNAs or proteins are presented in the BD patient group, or what concentrations of microRNAs or proteins are significantly different between the BD patients and MDD patients. Improving the early diagnosis of BD would help develop appropriate clinical intervention strategy, improve the quality of disease management, and significantly reduce the burden of disease. At the same time, this study is also hope to provide a theoretical basis for exploring the pathogenesis of bipolar disorder.
| Condition or disease |
|---|
| Bipolar Affective Disorder Major Depressive Disorder |
| Study Type : | Observational |
| Estimated Enrollment : | 130 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Other |
| Official Title: | Study on Exosomes for Identifying Bipolar Affective Disorder in Early Stage |
| Estimated Study Start Date : | June 15, 2023 |
| Estimated Primary Completion Date : | June 30, 2024 |
| Estimated Study Completion Date : | December 31, 2024 |
| Group/Cohort |
|---|
|
BD group
patients with bipolar disorder for the first stage
|
|
MDD group
patients with major depressive disorder for the first stage
|
|
healthy control
participants without psychosis for the first stage
|
|
BD group II
patients with bipolar disorder for the second stage
|
|
MDD group II
patients with bipolar disorder for the second stage
|
- accuracy of predicting diagnosis [ Time Frame: 6.15.2023-6.30.2024 ]the rate of patients got diagnosis indicated by biomarkers consistent with the diagnosis by DSM-5
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Bipolar disorder group:
Inclusion criteria: ① Meets the diagnostic criteria for bipolar disorder in DSM-5; ② Han ethnicity, any gender, aged 18-60 years old; ③ Initial symptoms were depressive episodes.
Exclusion criteria: ① Meets the diagnostic criteria for other mental disorders in DSM-5; ② Accompanied by severe physical illnesses, including uncontrolled hypertension, severe cardiovascular, cerebrovascular, pulmonary diseases, thyroid diseases, diabetes, epilepsy, metabolic syndrome, etc.; ③ History of alcohol abuse or use of other psychoactive substances; ④ Pregnant or lactating women; ⑤ Any factors that hinder the participant from providing informed consent or participating in the study.
Major depressive disorder group:
Inclusion criteria: ① Meets the diagnostic criteria for depressive episodes in DSM-5; ② Han ethnicity, any gender, aged 18-60 years old; ③ A history of illness of no less than 5 years.
Exclusion criteria: Same as bipolar disorder group.
Healthy control group:
Inclusion criteria: ① No mental disorders that meet the diagnostic criteria in DSM-5; ② Han ethnicity, any gender, aged 18-60 years old.
Exclusion criteria: ① Any mental disorders that meet the diagnostic criteria in DSM-5 within two generations of the family; ② Accompanied by severe physical illnesses, including uncontrolled hypertension, severe cardiovascular, cerebrovascular, pulmonary diseases, thyroid diseases, diabetes, epilepsy, metabolic syndrome, etc.; ③ History of alcohol abuse or use of other psychoactive substances; ④ Pregnant or lactating women; ⑤ Any factors that hinder the participant from providing informed consent or participating in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05915312
| China | |
| Tianjin Anding Hospital | |
| Tianjin, China | |
| Contact: Chenghao Yang, PhD yts83420@163.com | |
| Responsible Party: | Tianjin Anding Hospital |
| ClinicalTrials.gov Identifier: | NCT05915312 |
| Other Study ID Numbers: |
2022KJ264 |
| First Posted: | June 23, 2023 Key Record Dates |
| Last Update Posted: | June 23, 2023 |
| Last Verified: | June 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | the data but no the blood sample can be shared based on the resonable request. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Exosome Early diagnosis microRNA |
|
Genetic Diseases, X-Linked Depressive Disorder Depressive Disorder, Major Mood Disorders |
Bipolar Disorder Mental Disorders Bipolar and Related Disorders Genetic Diseases, Inborn |